Home | News | Translational


Telomeres in mouse embryonic fibroblasts Innovation
EMBO Molecular Medicine. CNIO researchers find effective drug combinations for glioblastoma in mice Usually, scientists study the molecular biology of cancer to find new treatments, but sometimes, it...
Mouse lymph node Innovation
Journal of Experimental Medicine. CNIO researchers assess melanoma progression with a new liquid biopsy technique When the surgeon surgically removes a melanoma, some patients are said to be ‘cancer-free’ and...
DLST protein Innovation
The American Journal of Human Genetics. CNIO researchers identify a new gene involved in the development of a rare endocrine tumour Paragangliomas and phaeochromocytomas are very rare neuroendocrine tumours: there are only 3-8 cases...
Elena Castro and David Olmos Scientific News
Journal of Clinical Oncology. CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with...
Mielofibrosis Scientific News
Haematologica. The CNIO and Hospital 12 de Octubre find a potential new combination therapy against a rare disease of the bone marrow Myelofibrosis is a severe and very rare haematological disease for which treatment has only been...
Lung Cancer Clinical Research Unit H12O-CNIO Innovation
The New England Journal of Medicine (NEJM). An international clinical trial extends the effectiveness of immunotherapy to more lung cancer patients The strategy for triggering the patient’s own immune system to attack cancer, immunotherapy, is...
H12O-CNIO Haematological Malignancies Clinical Research Unit Innovation
Haematologica. A new methodology predicts the risk of relapse in patients with acute myeloid leukemia The acute myeloid leukemia (AML) is the most common haematological cancer in adults. With a 5-year...
David Olmos Innovation
European Urology. First blood-based biomarker in response to the treatment of the most aggressive prostate cancer In collaboration with British and Italian researchers
U.S. Department of Defense will finance a new therapeutic approach against the most aggressive type of prostate cancer Coinciding with ‘Movember’, a month that raises awareness of men’s health issues